SCHEMBL1558910

SCHEMBL1558910

Brc1ccc2ncc3nn(Cc4ccccc4)cc3c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.45
▸ HTT P42858 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ PIK3CD O00329 1/20 0.45
▸ PIK3R1 P27986 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ DYRK1B Q9Y463 1/20 0.43
▸ CCNC P24863 1/20 0.42
▸ CDK8 P49336 1/20 0.42
▸ GABRA1 P14867 1/20 0.42
▸ GABRG2 P18507 1/20 0.42
▸ GABRB3 P28472 1/20 0.42
▸ GABRA5 P31644 1/20 0.42
▸ GABRA3 P34903 1/20 0.42
▸ GABRA2 P47869 1/20 0.42
▸ GABRA6 Q16445 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1234045 0.83 TGFBR1 (0.49) LMNAKDM4EALDH1A1MAPTADORA3
SCHEMBL1128943 0.79 HDAC8 (0.50) LMNAHTTSMN1; SMN2KDM4EALDH1A1
SCHEMBL12266572 0.76 HTT (0.43) LMNAHTTSMN1; SMN2PIK3CDPIK3R1
SCHEMBL1129177 0.76 KDM4C (0.44) LMNAHTTSMN1; SMN2KDM4EALDH1A1
SCHEMBL1559545 0.75 LMNA (0.42) LMNAHTTSMN1; SMN2PIK3CDPIK3R1
SCHEMBL1558176 0.75 RECQL (0.46) LMNAHTTSMN1; SMN2PIK3CDPIK3R1
SCHEMBL5076661 0.72 ADORA3 (0.40) LMNADYRK1BMAPTKMT2AADORA3
SCHEMBL24879334 0.71 ADORA3 (0.42) LMNASMN1; SMN2ALDH1A1MAPTADORA3
SCHEMBL1169735 0.71 HDAC8 (0.49) ADORA3ADORA2AADORA1TGFBR1MAPK14
SCHEMBL29723994 0.69 GRK2 (0.65) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 — — US disclosed
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 — — US disclosed
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 — — US disclosed
EP-2303890-A2 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS Progenics Pharmaceuticals, Inc. (US) 2011-04-06 — — EP disclosed
WO-2009155527-A9 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. (US) 2010-05-06 — — WO disclosed
WO-2009155527-A2 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. (US) 2009-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PIK3CA, AKT1, PIK3R5 LMNA 2658/4885HTT 2663/4885SMN1; SMN2 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback